JPM vs LX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
LX presents a classic 'deep value' paradox: it is fundamentally cheap but experiencing severe growth decay. The Piotroski F-Score of 6/9 indicates stable financial health, and the stock trades at a massive discount to its Graham Number ($18.21) and Intrinsic Value ($10.01). However, this valuation is offset by a 0/100 technical trend and alarming YoY earnings contraction of -39.80%. While the dividend is highly attractive and well-covered, the lack of growth and bearish momentum suggest a potential value trap.
Compare Another Pair
Related Comparisons
JPM vs LX: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and LexinFintech Holdings Ltd. (LX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.